GT Biopharma, Inc. (GTBP)

GT Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	6	11	29	93	33	5
Market Cap Growth	-69.79%	-63.37%	-69.08%	181.07%	507.58%	-83.27%
Enterprise Value	-4	-3	12	61	54	19
PE Ratio	-	-1.39	-1.38	-1.61	-1.17	-0.14
PB Ratio	1.12	1.41	2.46	4.26	-1.13	-0.28
P/FCF Ratio	-0.61	-1.19	-1.90	-5.98	-4.57	-1.58
P/OCF Ratio	-0.61	-1.19	-1.90	-5.98	-4.57	-1.49
EV/EBITDA Ratio	0.38	0.45	-0.60	-1.07	-2.14	-0.51
EV/EBIT Ratio	0.38	0.45	-0.60	-1.07	-2.14	-0.51
EV/FCF Ratio	0.36	0.38	-0.82	-3.93	-7.47	-5.43
Debt / Equity Ratio	0.01	0.01	0.01	0.00	-0.89	-0.70
Debt / EBITDA Ratio	0.00	-0.01	-0.01	0.00	-1.04	-0.37
Debt / FCF Ratio	0.00	-0.01	-0.01	0.00	-3.63	-3.86
Quick Ratio	2.13	2.11	3.34	3.12	0.15	0.00
Current Ratio	2.15	2.12	3.35	3.14	0.16	0.01
Interest Coverage	-9635.00	-34.67	-2609.50	-79.80	-8.42	-17.16
Return on Equity (ROE)	-111.50%	-71.80%	-137.10%	-202.50%	105.70%	862.30%
Return on Assets (ROA)	-66.10%	-44.40%	-93.40%	-171.70%	-1426.20%	-296.60%
Return on Capital (ROIC)	-243.39%	-180.20%	-178.51%	-262.13%	218.26%	277.64%
Earnings Yield	-162.47%	-71.93%	-72.42%	-62.19%	-85.27%	-707.56%
FCF Yield	-170.45%	-83.81%	-52.77%	-16.73%	-21.88%	-63.33%
Buyback Yield / Dilution	-27.50%	-26.87%	-13.19%	-542.06%	-29.59%	-14.50%
Total Shareholder Return	-27.50%	-26.87%	-13.19%	-542.06%	-29.59%	-14.50%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).